White Papers

Provided By:

Cello Health

September 7, 2017

The rare disease landscape is changing: with assets being granted expedited review, launch is no longer a fixed point in time, and research and development (R&D), medical affairs, and commercial teams need to collaborate early in the process to reach critical consensus o … Read More »

Provided By:

Evidera

August 31, 2017

Rapid-cycle analytic technologies represent an important advance in the pursuit of improved evidence generation practices – but this is only the first step. Learn how RWE technology is evolving through standardization, efficiency, and democratization of data.

Provided By:

Medidata Solutions

August 1, 2017

Globalization of clinical trials, tightening regulatory requirements, a more competitive and collaborative commercial environment, and an increasingly mobile workforce requires life-sciences companies to standardize and improve regulated content management processes to ensur … Read More »

Provided By:

Schulman IRB

July 14, 2017

The therapeutic landscape is shifting rapidly, and it’s becoming more and more important for those involved in overseeing clinical research to be familiar with the latest breakthroughs and treatments. Increasing sophistication in the design, conduct, and analysis of clinical … Read More »

Provided By:

Greenphire

June 1, 2017

Investigative site payments have long been recognized as a major pain point along the drug development continuum. Too often, the processes by which payments to sites by contract research organizations (CROs) and Sponsors are made are complicated, burdensome, time-consuming, … Read More »

Provided By:

goBalto

May 25, 2017

This white paper describes how standardized performance metrics designed to measure various sub-steps help to optimize the SSU process by providing transparency into the following bottlenecks that could derail study activation, cycle times and budgets: • Contract negotiation … Read More »

Provided By:

TrialCard

May 22, 2017

Virtual engagement strategies are evolving the way the pharmaceutical industry connects with key stakeholders. By using a blend of technology and experienced personnel to seamlessly connect brands to healthcare professionals, virtual engagement offers a solution to the trend … Read More »

Provided By:

Dohmen

May 18, 2017

Neither orphan drug manufacturers nor their patients with rare diseases are served well by the traditional multi-channel model of drug delivery and patient service. A new integrated model increases adherence and improves patient outcomes, which in turn leads to better financ … Read More »

Provided By:

inVentiv Health

April 6, 2017

No group of stakeholders wields greater influence over patient access to medicines than payers making reimbursement and formulary decisions. Even in a time of policy upheaval in Washington, health plans must make sure members get the medicines they need. Insurers say they’re … Read More »

Provided By:

DocuSign

April 3, 2017

Life science companies are experiencing a significant transformation in how they bring new products to market. Organizations must adapt to changes in the marketplace, such as global product commercialization, specialized medicine, new regulations, new payment models, and new … Read More »

Provided By:

Cardinal Health Regulatory Sciences

April 3, 2017

For patients with serious and rare diseases, time is of the essence, and the traditional drug development process may take far too long. To speed innovative new drugs to market, the FDA has established four expedited programs that allow the development process to be compress … Read More »

Provided By:

Medidata Solutions

March 31, 2017

Mobile apps are an important link between researchers and patients, but using them in clinical development requires rigorous preparation. Download this white paper to learn more about data strategies for mobile apps throughout the trial life cycle, the current and future reg … Read More »

Provided By:

DrugDev

March 24, 2017

Smaller companies have unique needs in regards to clinical trials. Historically, vendors have approached the clinical trials industry with a “one size fits all” technology approach that is too big, expensive and cumbersome to maintain, or provides little actual value for wha … Read More »

Provided By:

eyeforpharma

March 7, 2017

In our ever-more patient-centric world, a key question arises – what do patients think about DTC? Health Perspectives Group, experts in patient engagement since 2002, partnered with eyeforpharma to answer this question in today’s changing environment. They contacted the Food … Read More »

Provided By:

Chiltern

March 6, 2017

In this white paper, we’ll discuss the guidances compelling organizations to compile data into standardized, digital datasets, the FDA’s motivation behind these changes and the benefits to — as well as the hopes of — the organizations that must submit standardized data. Ther … Read More »

Provided By:

Rx EDGE Pharmacy Networks

February 9, 2017

Today’s consumers have choices about how and where they gather pertinent health information, and conversely, pharmaceutical companies have endless options on how, when and where to reach them. The plethora of options introduces a new quandary—where to begin? This white paper … Read More »

Provided By:

inVentiv Health

January 31, 2017

Through sustained partnerships between advocacy and industry, the US and Europe can overcome barriers to care. As a source of human suffering, a barrier to workplace productivity, a burden on families and a driver of medical costs, mental illness amounts to an unparalleled p … Read More »

Provided By:

Atlantis Healthcare

December 15, 2016

A stand-out digital solution is one that is highly valued by the patient, seamlessly integrated, and delivers measurable results, such as improved health outcomes. Learn about an established process and infrastructure to design, implement and measure digital tools. Increasin … Read More »

Provided By:

Sciformix Corporation

December 1, 2016

While development of promising new products is an obvious area of focus for biopharmaceutical companies, maintenance of already established marketed products is a critical activity that cannot be ignored. As products mature, there is high pressure to grow or sustain revenue … Read More »

Provided By:

Atlantis Healthcare

October 19, 2016

The self-management challenges for people living with chronic conditions are broad and are influenced by a range of factors, both internal and external to the individual. This report outlines how when designing support systems and programs to aid self-management, it is impor … Read More »

Provided By:

Chiltern

October 3, 2016

To manage chronic medical conditions, real-time monitoring of disease-specific physiologic metrics is becoming an important part of standard of care, and smartphone technology is making it possible. Existing smartphone interfacing devices now record health parameters and met … Read More »

Provided By:

Cognizant

September 27, 2016

The rise of generic medicines, regulatory pressure, and rampant consumer adoption of technology demands that the life sciences industry adopt a more direct and value-driven engagement to remain competitive. Harnessing digital technology allows you to meet these new industry … Read More »

Provided By:

Manatt Health

September 13, 2016

While the Affordable Care Act continues to be politically polarizing, stakeholders from across the health reform landscape are focused on effectively implementing the law and on making incremental – not radical – changes to it. The question is how such change might happen gi … Read More »

Provided By:

myClin

August 30, 2016

Regulatory scrutiny in clinical research has intensified in recent years, and there are no signs that the intensity of the regulatory environment is abating. In the context of increased outsourcing of clinical study activity to CROs, inspectors are showing an increased inter … Read More »

Provided By:

C3i Healthcare Connections

August 29, 2016

Findings reveal that based on the industry’s current level of participation in social media, utilization of technology, and effectiveness of social programs, the pharma industry is in the early stages of social media maturity. In fact, only 13% of those that participated in … Read More »

Provided By:

Cello Health

August 15, 2016

An estimated 400 million people worldwide are currently living with rare diseases. There are approximately 7,000 different types of rare diseases and disorders, with more being discovered every day. At best, the knowledge base about any individual rare disease is small, frag … Read More »

Provided By:

Schulman IRB

July 28, 2016

Managing an efficient, well-organized start-up phase is critical to overall study success. While IRB review is just one element of the study start-up process, the IRB can play a crucial role in reaching key study milestones in multisite clinical trials for sponsors, CROs and … Read More »

Provided By:

TrialCard

July 28, 2016

If you have ever worked with Orphan Drugs, you know finding appropriate patients is a major commercial challenge. Pharmaceutical sponsors of Orphan Drugs often lack the infrastructure and capabilities necessary to identify physicians who diagnose, treat, and manage these rar … Read More »

Provided By:

Health Perspectives Group

September 8, 2015

This analysis of real-world examples and research shows the relationship between emotional connections, shared values and consumer behavior and discusses four ways biopharma companies can apply these elements to build brand loyalty. There is also a related podcast on this to … Read More »

Provided By:

TrialCard

August 24, 2015

As the healthcare landscape moves increasingly toward outcome-based treatment approaches, the need to gather and analyze real-world outcome data has become paramount to gauging medication effectiveness and subsequently recruiting prescribers as brand advocates. This study ou … Read More »

Provided By:

TrialCard

August 17, 2015

The healthcare industry has been wringing its collective hands for years about the problems surrounding “patient engagement.” Beyond the fact that no one has a really good definition of what constitutes patient engagement, most everyone agrees that if you have more patient e … Read More »

FEEDBACK